請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

PR Newswire (美通社)

更新於 2天前 • 發布於 2天前 • PR Newswire

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 28, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period").

Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$68 million (equivalent to approximately HK$532 million) and US$74 million (equivalent to approximately HK$579 million).

The anticipated increase in profit is primarily attributable to:

  • Continuing strategic partnerships with leading global pharmaceutical companies, including the global strategic collaboration with AstraZeneca.
    - The Company has received gross proceeds totaling approximately US$175 million from the allotment and issuance of the subscription shares, as well as partial upfront, milestone, and option exercise fees.
  • Newly secured out-licensing and collaboration agreements for innovative products, which contributed significantly to revenue during the Reporting Period and are evolving into a normalized revenue stream of the Company.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: "This anticipated improvement in profitability underscores the meaningful progress we've made in executing our strategic priorities. The performance reflects the strength of our diversified business model and our ability to translate scientific innovation into tangible value. We will continue to build on this momentum through innovation and high-impact collaborations to deliver sustainable growth."

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit .

Statement

The information contained in this press release is only a preliminary assessment by the Board based on the unaudited management accounts of the Company and its subsidiaries for the six months ended June 30, 2025 currently available to the Company, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board, or reviewed or audited by the auditors of the Company. The actual results for the six months ended June 30, 2025 may differ from those disclosed in this press release. As such, the above figures are strictly for information only and not for any other purposes.

查看原始文章

Global Times: How 'investing in the people' benefits the whole society in China

PR Newswire (美通社)

AESTURA, Korea's #1 Dermatologist-Recommended Dermocosmetic Brand Launches Exclusively at Sephora Australia

PR Newswire (美通社)

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

最新內容

Update: China to allocate 90 billion yuan for nationwide childcare subsidies

XINHUA

Scorching heat fuels China's booming nighttime tourism

XINHUA

Update: Cambodia, Thailand reaffirm commitment to ceasefire agreement at trilateral meeting with China

XINHUA

China launches low Earth orbit satellite group

XINHUA

China, U.S. trade talks in-depth, candid, constructive, says China int'l trade representative

XINHUA

Study tour boom fuels China's countryside revival

XINHUA

The Philippines is troublemaker in South China Sea: defense ministry

XINHUA

Xinhua Commentary: Don't let peace in Gaza become a castle in the air

XINHUA

Xinhua News | CPC leadership holds symposium to seek advice on economic work

XINHUA

10 confirmed dead after bus goes missing in north China

XINHUA

CLO Unveils the zFab Kit: a Revolutionary AI-Powered Fabric Digitization System

PR Newswire (美通社)

China's Gen-Zers seek ancient healing at TCM night markets

XINHUA

Emerald Clinical Trials Confirms CEO Transition and Continuity Plan

PR Newswire (美通社)

Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company

PR Newswire (美通社)

FlyOverChina | A glimpse of night market in north China's Zhengding

XINHUA

Chinese, Russian navies to hold joint exercise, maritime patrol

XINHUA

China announces 14-man roster for final FIBA Asia Cup preparations

XINHUA

China hopes certain countries not to be swayed by "Taiwan independence" forces: spokesperson

XINHUA

GLOBALink | FPV drone tour of picturesque Chengkan Village in E China

XINHUA

Chancay-Shanghai shipping route boosts China-Peru trade

XINHUA

Update: CPC leadership holds symposium to seek advice on economic work

XINHUA

Xinhua News | China to earmark 90 billion yuan for childcare subsidies

XINHUA

Chery Group rejoins Fortune Global 500; LEPAS debuts at Jakarta Auto Show with first overseas orders

PR Newswire (美通社)

State Grid Gansu Linxia Power Supply Company: Strong Grid to Support Local Revitalization and Development

PR Newswire (美通社)

aiMotive Signs License Agreement with Socionext for aiWare NPU IP to Power Next-Gen ADAS SoC

PR Newswire (美通社)

WWII bond lives on as U.S. students pay tribute to Flying Tiger rescued by Chinese people

XINHUA

Thailand EV Board Adjusts EV3, EV3.5 Terms to Promote Exports as Investment in EV Supply Chain Tops 137 Billion Baht

PR Newswire (美通社)

10 confirmed dead after bus goes missing in north China

XINHUA

AI visionaries converge in Shanghai to chart the future of innovation

PR Newswire (美通社)

Chinese scientists unveil new insights into glacier melting in Central Asia

XINHUA

Chinese FM spokesperson briefs on latest round of China-U.S. trade talks

XINHUA

MetaOptics Ltd Lodges Preliminary Offer Document for Catalist Listing on the SGX-ST

PR Newswire (美通社)

SuperX Unveils the All-New SuperX XN9160-B200 AI Server, Powered by NVIDIA Blackwell GPU -- Accelerating AI Innovation by 30x as Compared to H100 Series with Supercomputer-Class Performance

PR Newswire (美通社)

War-scarred hinterlands reborn as prosperous mountain retreats

XINHUA

Hikvision unleashes the power of large-scale AI in traffic management by introducing next-generation traffic cameras and servers

PR Newswire (美通社)

Technology Drives Creativity: Digital Domain Showcases R&D Achievements at WAIC 2025

PR Newswire (美通社)

5th China-Mongolia Expo to boost regional cooperation

XINHUA

GLOBALink | Global youth unite in China to honor history and advocate for peace

XINHUA

Barry Callebaut Inaugurates Third Chocolate Factory in Neemrana, India

PR Newswire (美通社)

(Hello Africa) Cameroon hails health cooperation with China for half a century

XINHUA